Quotient Sciences Quotient Sciences

X

Find the latest Drugs in Development and Pipeline Prospector News of Aditxt.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Aditxt
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
Richmond, VA 23219
Telephone
Telephone
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Under the terms of the agreement, Aditxt will acquire Appili along with its pipeline, which includes the ATI-1701 vaccine. Currently, the vaccine is undergoing evaluation in preclinical trials for the treatment of tularemia.


Lead Product(s): ATI-1701

Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-1701

Highest Development Status: PreclinicalProduct Type: Vaccine

Recipient: Appili Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement April 02, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Through the acquisition of Evofem, Aditxt gains access to its first and only FDA-approved hormone-free contraceptive gel, Phexxi (lactic acid, citric acid, and potassium bitartrate).


Lead Product(s): L-Lactic Acid,Citric Acid,Potassium Bitartrate

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Phexxi

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: Evofem Biosciences

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition December 12, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the agreement, Aditxt expands its portfolio to include innovative therapies for infectious diseases by including Avigan (favipiravir), an oral broad-spectrum inhibitor of viral RNA-dependent RNA polymerase.


Lead Product(s): Favipiravir

Therapeutic Area: Infections and Infectious Diseases Product Name: Avigan

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Cellvera

Deal Size: $10.0 million Upfront Cash: $10.0 million

Deal Type: Agreement April 20, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

ADI™-100 consists of two DNA molecules, which together restore immune tolerance in autoimmune disease and establish tolerance in allogeneic skin transplantation applied in large skin wounds.


Lead Product(s): ADI-100

Therapeutic Area: Dermatology Product Name: ADI-100

Highest Development Status: PreclinicalProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 21, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The company intends to use the net proceeds for general corporate purposes, which may include research and development expenses for plasmid DNA-based therapeutics, capital expenditures, working capital and general and administrative expenses.


Lead Product(s): Plasmid DNA-based Therapeutic

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Large molecule

Partner/Sponsor/Collaborator: H.C. Wainwright & Co

Deal Size: $20.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering September 16, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

ADI-100 consists of two DNA molecules, which together restore immune tolerance in autoimmune disease and establish tolerance in allogeneic skin transplantation applied in large skin wounds.


Lead Product(s): ADI-100

Therapeutic Area: Immunology Product Name: ADI-100

Highest Development Status: PreclinicalProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 08, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Cellvera holds worldwide rights (except Japan) to a broad spectrum oral antiviral drug targeting COVID-19 and other infectious diseases. Cellvera is focused on developing and commercializing antimicrobial therapies across a broad spectrum infectious diseases including Avigan.


Lead Product(s): Favipiravir

Therapeutic Area: Infections and Infectious Diseases Product Name: Avigan

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: Cellvera

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement April 05, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY